Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.76 |
| ▸ | MMP8 | P22894 | 1/20 | 0.76 |
| ▸ | NPC1 | O15118 | 1/20 | 0.71 |
| ▸ | KDR | P35968 | 5/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16458931 | 0.94 | MMP2 (0.86) | MMP2MMP8NPC1KDRLMNA | |
| SCHEMBL15401066 | 0.90 | KDR (0.74) | MMP2MMP8NPC1KDRLMNA | |
| SCHEMBL24993422 | 0.87 | SMN1; SMN2 (0.67) | MMP2MMP8NPC1KDRLMNA | |
| SCHEMBL30173489 | 0.87 | SMN1; SMN2 (0.67) | MMP2MMP8NPC1KDRLMNA | |
| SCHEMBL3396536 | 0.83 | NPC1 (0.64) | MMP2MMP8NPC1KDRLMNA | |
| SCHEMBL24993421 | 0.83 | MMP2 (0.80) | MMP2MMP8NPC1KDRLMNA | |
| SCHEMBL28247801 | 0.82 | NPC1 (0.80) | MMP2MMP8NPC1LMNAUSP2 | |
| SCHEMBL16434393 | 0.82 | MMP2 (0.66) | MMP2MMP8NPC1KDRLMNA | |
| SCHEMBL15403403 | 0.81 | ACHE (0.74) | MMP2MMP8KDRLMNAUSP2 | |
| SCHEMBL19956359 | 0.81 | MMP2 (0.66) | MMP2MMP8NPC1KDRTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2682121-B1 | PHARMACEUTICAL USE OF AMINOTHIAZOLE MYD88 SPECIFICITY INHIBITOR | WUHAN INNAMUNE PHARMACEUTICAL CO LTD (CN) | 2018-03-14 | — | — | EP | claimed |
| EP-2682121-A1 | PHARMACEUTICAL USE OF AMINOTHIAZOLE MYD88 SPECIFICITY INHIBITOR | Tongji Hospital Tongji Medical College Huazhong University of Science and Technology (CN) | 2014-01-08 | — | — | EP | claimed |
| CN-102166214-B | Medical application of aminothiazole MyD88 specific inhibitor | AFFILIATED TONGJI HOSPITAL OF TONGJI MEDICAL COLLEGE OF HUAZHONG UNIV SCI & TECH | 2012-12-12 | — | — | CN | claimed |
| CN-102166214-A | Medical application of aminothiazole MyD88 specific inhibitor | AFFILIATED TONGJI HOSPITAL OF TONGJI MEDICAL COLLEGE OF HUAZHONG UNIV SCI & TECH | 2011-08-31 | — | — | CN | claimed |
| US-20240180898-A1 | USE OF AMINOTHIAZOLE DERIVATIVE IN TREATMENT OF IMMUNE INFLAMMATION | INNAMUNE PHARMACEUTICAL CO. LTD. (CN) | 2024-06-06 | — | — | US | disclosed |
| WO-2023011609-A1 | USE OF AMINOTHIAZOLE DERIVATIVE IN PREPARATION OF IMMUNOLOGICAL INFLAMMATORY DRUG | 宁波亿诺药业有限公司 | 2023-02-09 | — | — | WO | disclosed |
| EP-3424912-A1 | 2-AMINOTHIAZOLE DERIVATIVES FOR MEDICAL USE | Huazhong University of Science and Technology (CN) | 2019-01-09 | — | — | EP | disclosed |
| EP-2682121-B1 | PHARMACEUTICAL USE OF AMINOTHIAZOLE MYD88 SPECIFICITY INHIBITOR | WUHAN INNAMUNE PHARMACEUTICAL CO LTD (CN) | 2018-03-14 | — | — | EP | disclosed |
| EP-2682121-B1 | PHARMACEUTICAL USE OF AMINOTHIAZOLE MYD88 SPECIFICITY INHIBITOR | WUHAN INNAMUNE PHARMACEUTICAL CO LTD (CN) | 2018-03-14 | — | — | EP | disclosed |
| US-9771340-B2 | 2-aminothiazole derivatives and methods of preparing and using the same | WUHAN INNAMUNE PHARMACEUTICAL CO., LTD. (CN) | 2017-09-26 | — | — | US | disclosed |
| EP-2682390-A1 | 2-AMINOTHIAZOLE DERIVATIVE, PREPARATION METHOD, AND USE | Huazhong University of Science and Technology (CN) | 2014-01-08 | — | — | EP | disclosed |
| EP-2682121-A1 | PHARMACEUTICAL USE OF AMINOTHIAZOLE MYD88 SPECIFICITY INHIBITOR | Tongji Hospital Tongji Medical College Huazhong University of Science and Technology (CN) | 2014-01-08 | — | — | EP | disclosed |
| EP-2682121-A1 | PHARMACEUTICAL USE OF AMINOTHIAZOLE MYD88 SPECIFICITY INHIBITOR | Tongji Hospital Tongji Medical College Huazhong University of Science and Technology (CN) | 2014-01-08 | — | — | EP | disclosed |
| US-20140004155-A1 | 2-AMINOTHIAZOLE DERIVATIVES AND METHODS OF PREPARING AND USING THE SAME | HANGZHOU ZHONGMEI HUADONG PHARMACEUTICAL CO., LTD. (CN) | 2014-01-02 | — | — | US | disclosed |
| CN-102166214-B | Medical application of aminothiazole MyD88 specific inhibitor | AFFILIATED TONGJI HOSPITAL OF TONGJI MEDICAL COLLEGE OF HUAZHONG UNIV SCI & TECH | 2012-12-12 | — | — | CN | disclosed |
| CN-102166214-A | Medical application of aminothiazole MyD88 specific inhibitor | AFFILIATED TONGJI HOSPITAL OF TONGJI MEDICAL COLLEGE OF HUAZHONG UNIV SCI & TECH | 2011-08-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140004155-A1 | 2-AMINOTHIAZOLE DERIVATIVES AND METHODS OF PREPARING AND USING THE SAME | CCNT1, CCNE1, CCNT2 | MMP2 3265/4885MMP8 4190/4885NPC1 3122/4885 |
| US-20240180898-A1 | USE OF AMINOTHIAZOLE DERIVATIVE IN TREATMENT OF IMMUNE INFLAMMATION | AADAT, IDO1, IDO2 | MMP2 2870/4885MMP8 1107/4885NPC1 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.